UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, ~~D.C.~~DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: ~~March~~(Date of earliest event reported): July 31, 2025

REGENEREX PHARMA, INC.

(Exact ~~name~~Name of ~~registrant~~Registrant as ~~specified~~Specified in its ~~charter~~ Charter)

Nevada	000-53230	98-0479983
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

5348 Vegas Drive #177

5348 Vegas Drive #177

Las Vegas, NV

89108

(Address of Principal Executive Offices)

(Zip Code)

~~Las~~Registrant’s ~~Vegas~~telephone number, NVincluding ~~89108~~area code: (877) 761-7479

~~(Address~~Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of ~~principal~~the ~~executive~~registrant under ~~offices~~any of the following provisions (see General Instruction A.2. below):

(877) 761-7479

Registrant’s telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

~~Title~~Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of ~~each~~the ~~class~~Securities ~~Trading~~Act ~~Symbol~~of 1933 (s§230.405 of this chapter) or ~~Name~~Rule 12b-2 of ~~each~~the ~~exchange~~Securities onExchange ~~which~~Act ~~registered~~of ~~Common~~1934 (§240.12b-2 ~~RGPX~~of ~~N/A~~this chapter).

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

~~SECTION~~Item 51.01 - ~~CORPORATE~~Entry ~~GOVERNANCE~~into ~~AND~~a ~~MANAGEMENT~~Material Definitive Agreement

~~Item~~New Contract ~~5.02~~with ~~Departure~~Holista ofColltech ~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Ltd.

~~Appointment~~As part of ~~Certain~~the ~~Officers~~Company’s strategic advancement, Regenerex has entered into a licensing agreement with Holista Colltech Ltd. (“Holista”), a globally recognized producer of high-purity ovine collagen. This includes exclusive rights to use in wound care and distribution rights in the USA.

~~Effective~~Regenerex ~~March 31~~Pharma, ~~2025, Mr~~Inc. ~~Kenneth~~Enters W.Into ~~Perry~~Licensing Agreement ~~has~~with ~~been~~Holista ~~appointed~~Colltech ~~to serve as Chief Financial Officer for the company~~Ltd.

~~Mr. Kenneth~~New W.Wound ~~Perry~~Healing isBreakthrough ~~a seasoned CFO and senior finance executive with 39 years of experience in healthcare finance, revenue cycle management, supply chain operations, and information technology.~~ With ~~extensive leadership experience in~~Ovine the medical field, Ken has served as Division CFO for HCA, founded Lasis Healthcare, and led multiple healthcare organizations to financial success. His expertise spans system implementations and strategic leadership. Ken's balanced approach to problemNano-~~solving~~Collagen isQBx™ strengthened by his rare combination of finance, operations, IT knowledge and general accounting for public companies. A multiple award-winning CFO, he consistently delivers exceptional results, meeting KPIs and financial targets. Ken holds an MBA in Finance from Mississippi State University and a BS in Accounting from Tennessee Technological University.Integration

~~Effective~~July ~~March~~ 31, 2025- Las Vegas, ~~Mr.~~NV- ~~Brent~~Regenerex ~~Wilson~~Pharma, Inc ~~resigned~~(OTC: ~~his~~RGPX), ~~position~~a asleading ~~Chief~~innovator ~~Financial~~in ~~Officer~~advanced ofwound closure systems for chronic wounds, today announced the ~~Company~~development of new product formulations designed to accelerate deep tissue regeneration through enhanced scaffolding facilitation and cell proliferation. Building on its patented QBx™ technology, Regenerex will now incorporate ovine nano-collagen into its wound healing protocols. This highly refined biomaterial, due to ~~personal~~its ~~reasons~~ultra-small molecular size, provides an ideal scaffolding matrix to support and accelerate cellular growth, making it especially beneficial in cases requiring deeper tissue regeneration.

~~SIGNATURES~~As part of this strategic advancement, Regenerex has entered into a licensing agreement with Holista Colltech Ltd. (“Holista”), a globally recognized producer of high-purity ovine collagen. Holista’s collagen is derived from ethically sourced, disease-free Australian sheep, produced under Australia’s rigorous animal health standards.

~~Pursuant~~“Ovine tocollagen ~~the~~represents a significant step ~~requirements~~forward ofin ~~the~~wound ~~Securities~~care ~~Exchange~~innovation,” ~~Act~~said Greg Pilant, CEO of ~~1934~~Regenerex Pharma, Inc. ~~the~~“Unlike ~~Registrant~~traditional ~~has~~mammalian ~~duly~~sources such as bovine or porcine collagen, ~~caused~~ovine ~~this~~nano-collagen ~~Report~~is tonot beonly ~~signed~~safer—avoiding onconcerns ~~its~~like ~~behalf~~mad bycow disease—but ~~the~~also ~~undersigned,~~more ~~hereunto~~culturally ~~duly~~and religiously acceptable in many global ~~authorized~~markets. ”

		REGENEREX PHARMA, INC.
Date: April 2, 2025	By:	/s/ Gregory Pilant
		Gregory Pilant
		Chairman and CEO

This collaboration allows Regenerex to bring cutting-edge, biologically advanced wound care solutions to both U.S. and international markets. The integration of ovine nano-collagen with Regenerex’s QBx™ technology reflects the company’s commitment to providing safe, effective, and inclusive wound healing options.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.

	REGENEREX PHARMA, INC.

	By:	/s/ Greg Pilant
Date: July 31, 2025	Name:	Greg Pilant
	Title:	Chief Executive Officer

Filing Compare · REGENEREX PHARMA, INC.